Pre-made Olaratumab biosimilar ( Whole mAb, anti-PDGFRA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-393
Anti-PDGFRA therapeutic antibody (Pre-made Olaratumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDGFRA therapeutic antibody (Pre-made Olaratumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research|
|Conditions Approved||Soft tissue sarcoma|
|Conditions Active||Pancreatic cancer;Solid tumours|
|Conditions Discontinued||Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer|
|Development Tech||Medarex UltiMAb Mouse|